Does suicidality continue to occur among individuals with HIV engaged in care in the era of antiretroviral therapy?
Methods: Clinic patients completed a psychological and behavioral annual assessment during routine visits. Suicidal ideation was measured within the past 2 weeks using the PHQ-9. Anxiety symptoms were measured using the GAD-7. Medical markers were abstracted from medical records.
Results: A total of 628 participants were included in this study; 79 reported suicidal ideation in the previous 2 weeks. This occurred more often among individuals with unsuppressed viral loads, who endorsed moderate-severe anxiety symptoms, among women, those who considered themselves homeless, and who were unemployed (p <0.05 for all). Lastly, individuals reporting no sex partners in the previous 3 months were more likely to endorse suicidal ideation. There were no significant differences in average alcohol use, or CD4 cell count. Homeless individuals had 5.6 odds and those endorsing significant anxiety had 1.9 odds of reporting suicidality.
Conclusions: Even among populations with access to HIV care and medications, HIV infection seems to persist as a disease that is associated with socioeconomic challenges, psychological well-being, and gender. These findings heighten the need to address systemic problems by developing and testing multilevel interventions to address inequities in care experiences.
Planning of health education strategies, interventions, and programs
Social and behavioral sciences
Identify rates of suicidality among individuals with HIV engaged in care Describe sociodemographic and psychological distress factors related with suicidality
Keyword(s): Suicide, HIV/AIDS
Qualified on the content I am responsible for because: I am a doctoral student working on HIV research. I have worked on a multitude of research projects in this area and have extensive clinical knowledge as a licensed mental health professional.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.